Medpace has announced the relocation of its existing office in London. The new office, located at a new refurbished office on Hammersmith Grove, in London, supports Medpace European clinical operations groups operating in the UK and Europe. In addition, Medpace has relocated to expanded facilities in Poland and France to support a rapidly expanding EU market. Medpace, with 12 European offices serving 30 EU countries, continues to offer full-service innovation for studies in oncology, cardio metabolic, infectious disease, CNS, and other growing therapeutic areas. The UK offices in London and Stirling, Scotland, house close to 100 Medpace employees supporting clinical operations, regulatory, data management, quality assurance, and safety.
“The expansion of the office in London provides key thought leaders to support studies conducted in Europe,” said Dr. Axel Mescheder, Vice-President, Medical & Regulatory Affairs. “Medpace has experienced tremendous growth over the past three years and is committed to our European Sponsors who need to conduct studies in Western and Eastern Europe.”
Medpace established its first European office in the Czech Republic in 2005. Medpace employees in Europe now account for one third of Medpace global employees. All European offices are fully integrated with Medpace global development services.